

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**




FIG. 1




FIG. 2




FIG. 3

BEST AVAILABLE COPY

208




FIG. 4

BEST AVAILABLE COPY




FIG. 5




FIG. 6



Acme Pharmaceuticals

KDISCOVERER

700

User Name : 702

Password : 704

☒ Remember my user name and password


706

If you forget your password, please call 1-800-PASSWRD.

Copyright (c) 1999 - Andersen Consulting LLP. All rights reserved.

FIG. 7

BEST AVAILABLE COPY



Acme Pharmaceuticals **KDISCOVERER - Welcome!** [Edit Profile](#) [Sitemap](#) [Logout](#)

[Recent News](#) [Organizer](#) [Research](#) [Development](#) [Commercialization](#) [Search & Browse](#)

[Target](#)

◁ Acute Myocardial Infarction
 ◁ Angina Pectoris
 ◁ Cardiology
 ◁ Cholesterol
 ◁ Chronic Occlusive Arterial...

Cardiology/Vascular Diseases*

◁ 5-AMP Deaminase*
 ◁ ACE (Angiotensin-converting Enzyme)*
 ◁ Angiotensin Receptor*
 ◁ Antiarrhythmics
 ◁ Arteriolar
 ◁ Bronchodilator Agent
 ◁ Calcium Channel
 ◁ Coronary
 ◁ Digitalis Glycosides
 ◁ Epithelial Sodium Channel*
 ◁ Ganglionic Blocker
 ◁ Inotropic Drug
 ◁ Miscellaneous
 ◁ Non-Radiopaque Agent
 ◁ Peripheral
 ◁ Radiopaque Agent
 ◁ Selective C-Gmp. Phosphod...
 ◁ Sympatholytic
 ◁ Vasodilator
 ◁ Venotonics/Vasculoprotec...
 ◁ Venosclerosing Agent
 ◁ Veratrum Alkaloids
 ◁ Xanthines

THE MAIN
For evaluation use only

Therapeutic Area : Cardiology/Vascular Diseases

902

Quick Search and Browse [Search](#) [Help](#)

Copyright (c) 1999 - Andersen Consulting LLP.





FIG. 11

BEST AVAILABLE COPY



BEST AVAILABLE COPY

FIG. 13





FIG. 14 BEST AVAILABLE COPY

1600



Organizations

Merck

- FDA: 20560
- FDA: 20685
- Patent 4370829
- Alfuzosin is not associated with dermatomyositis.

Targets

TR27 K-channel

- Patent 4188390

Scientists

Ahiskali R

- The effect of losartan and captopril on glomerular basement membrane anionic charge in a diabetic rat model.

Smith, Donald R



Copyright (c) 1998 - Andersen Consulting LLP.

FIG. 16

BEST AVAILABLE COPY

1618




FIG. 17




FIG. 18A

BEST AVAILABLE COPY




FIG. 18B





FIG. 18C

BEST AVAILABLE COPY




1814

1822

FIG. 18D

BEST AVAILABLE COPY

FIG. 19






FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24




FIG. 25




FIGURE 26